- Recent capital raise removes liquidity risk.
- Last week's board of directors additions strengthen management depth.
- Sales commence in EU as of Q4 2013.
- U.S. trial may be Fast-Tracked.
- Neutrolin may be eligible for GAIN Act status.
Cormedix Inc is a development stage pharmaceutical and medical device company. It seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiorenal and infectious diseases, including the dialysis and non-dialysis areas.